Excellent results of Bomedemstat in the Phase 2 study’s ET and Myelofibrosis..

[Paul1993et]

Excellent results of Bomedemstat in the Phase 2 study’s ET and Myelofibrosis..

I think finally a very good successor for Hydrea.. This drug is not carcinogenetic and induces the mpn mutations to cell death.

(See conference posters downloadlinks) on:

imagobio.com/our-science/#pubs

[EPguy]

Thanks for the update. For ET it seems quite good on fatigue reduction, quite important.

One member here on the trial, Miriammusic, has an AE involving swollen foot.

healthunlocked.com/mpnvoice...

bomedemstat-and-question-sorry-so-long

I don't see that in the list, except "Pain in extremity 7 (10%)". (Miriammusic has confirmed this is not yet on the list)

The allele reductions are not in the easy to read layman's style we see in INF studies, but it looks promising at least for Jak2, while CALR is less. It would be good to separate the CALR by CALR type. I hope they provide more details there.

For MF trial one stand out is good reductions in ASXL1. This is an important non-driver mutation. Fibrosis reductions look decent. The planned Rux/Bom combo study seems interesting.

[FG251]

We need a ‘love’ emoji!